A once-daily patch could make one of pulmonary arterial hypertension’s most effective treatments easier for patients to live with.
Growing older is often associated with slowing down, but for people living with pulmonary arterial hypertension (PAH), even simple activities can become exhausting long before old age arrives.
The rare but devastating disease causes high blood pressure in the arteries connecting the heart and lungs, forcing the heart to work harder with every beat. Patients frequently experience breathlessness, fatigue and declining physical function, symptoms that can dramatically erode quality of life. While PAH can affect people of all ages, older adults often face an additional challenge: managing a complex treatment regimen alongside the realities of aging.
That is why a positive Phase 1 trial announced by California-based Corsair Pharma is attracting attention. The company’s investigational TRX-248 Transdermal System, a once-daily patch designed to deliver the established PAH drug treprostinil, has completed its first study in humans, potentially opening the door to a simpler way of administering one of the disease’s most effective therapies [1].
The results are still early. The study involved just nine healthy volunteers and was designed primarily to assess safety and drug delivery. Yet behind the numbers lies a broader question that increasingly matters across medicine and longevity science alike: can treatments be made easier to live with?
Goodbye pumps, hello patches?
For many PAH patients, the challenge is not simply taking medication; it’s how the medication must be delivered.
Treprostinil belongs to a class of drugs known as prostacyclins, widely considered among the most effective therapies available for PAH. Yet existing delivery methods can create significant burdens. Some patients rely on continuous subcutaneous infusions, which can trigger painful reactions at the infusion site. Others require intravenous lines that must remain in place around the clock, introducing practical complications and ongoing infection risks. These approaches work, but they can also serve as constant reminders of illness.
Corsair’s vision is straightforward: replace much of that complexity with a patch applied once daily. In the Phase 1 study, the TRX-248 patch maintained steady levels of treprostinil in the bloodstream for 24 hours following a single application. Importantly, the company also reported acceptable skin tolerability.
The appeal goes beyond convenience. Chronic diseases often carry a hidden psychological burden that rarely appears in clinical data. Treatments that require pumps, tubing or invasive administration can become part of a patient’s identity, shaping everything from travel plans to social interactions.
A discreet patch may seem like a small innovation, but for patients managing a lifelong condition, reducing daily treatment friction can have an outsized impact.
“This positive results provide further evidence that the Corsair Transdermal System may improve the lives of PAH patients,” said George Mahaffey, CEO of Corsair Pharma.
The liver’s surprising role
The science behind the patch is arguably as interesting as the patch itself. Traditionally, delivering vasodilator drugs through the skin has proven difficult. Many compounds either fail to penetrate effectively or cause irritation where they are applied.
Corsair is attempting to solve that problem by taking an indirect route. Rather than delivering active treprostinil through the skin, the patch administers TRX-248, an inactive precursor known as a prodrug. Once absorbed, it enters the bloodstream and travels to the liver, where it is rapidly converted into active treprostinil.
An easy way to think about it is as a package that remains sealed during transit and is only opened once it reaches its destination. By keeping the active drug “switched off” during its journey through the skin, the approach may help explain why the company observed acceptable skin tolerability in the study. The strategy also appeared capable of maintaining the steady drug exposure that physicians seek when treating PAH.
The company reported continuous treprostinil levels throughout the day with relatively little fluctuation, a finding that compared favorably with published data from subcutaneous delivery systems.
“We are excited by these first-in-human results demonstrating steady, therapeutically meaningful treprostinil levels using our proprietary prodrug and transdermal technology,” said Dr Bobby Singh, president and COO of Corsair Pharma. “These data support the potential of our transdermal platform as a clinically meaningful alternative to existing treprostinil delivery modalities.”
A growing market and a growing opportunity
The commercial implications are substantial. According to Corsair, prostacyclin therapies generate more than $3.3 billion annually in the United States, with treprostinil accounting for approximately $2 billion of that market.
Yet despite their effectiveness, many patients remain unwilling or unable to use these therapies because of the challenges associated with current delivery systems. If Corsair can demonstrate comparable efficacy with a less burdensome approach, it could address an important unmet need while competing within an already established market.
The company will present additional Phase 1 findings at the 2026 Pulmonary Hypertension Association Conference in Dallas later this month [2].
The longevity lesson
Longevity innovation is often associated with futuristic therapies, gene editing or age-reversal technologies, but sometimes progress arrives in a much simpler form.
For people living with chronic diseases, healthspan is influenced not only by whether treatments exist but by whether patients can realistically stick with them over years or even decades. A therapy that fits more naturally into daily life may ultimately prove just as important as a new drug itself.
Corsair’s patch remains early in development, and much larger patient studies lie ahead. Still, its first human data point toward a future where treatment design considers not only biological effectiveness but also the lived experience of patients.
The shift, from treating disease to reducing the burden of treatment itself, may become one of the most important healthcare trends of the coming decade. For patients with PAH, it could mean that managing a serious illness no longer has to feel like a full-time job.
[1] https://www.corsairpharma.com/corsair-pharma-announces-positive-phase-1-results-for-the-trx-248-transdermal-system-in-pulmonary-arterial-hypertension/
[2] https://www.corsairpharma.com/corsair-pharma-announces-three-presentations-of-phase-1-clinical-data-for-trx-248-transdermal-system-at-the-2026-pulmonary-hypertension-association-conference/
